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Abstract
In this review, we discuss T-cell activation, etiology, and the current therapies of autoimmune 
diseases (i.e., MS, T1D, and RA). T-cells are activated upon interaction with antigen-presenting 
cells (APC) followed by a “bull’s eye”-like formation of the immunological synapse (IS) at the T-
cell–APC interface. Although the various disease-modifying therapies developed so far have been 
shown to modulate the IS and thus help in the management of these diseases, they are also known 
to present some undesirable side effects. In this study, we describe a novel and selective way to 
suppress autoimmunity by using a bifunctional peptide inhibitor (BPI). BPI uses an intercellular 
adhesion molecule-1 (ICAM-1)-binding peptide to target antigenic peptides (e.g., proteolipid 
peptide, glutamic acid decarboxylase, and type II collagen) to the APC and therefore modulate the 
immune response. The central hypothesis is that BPI blocks the IS formation by simultaneously 
binding to major histocompatibility complex-II and ICAM-1 on the APC and selectively alters the 
activation of T cells from TH1 to Treg and/or TH2 phenotypes, leading to tolerance.
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1. IMMUNOLOGICAL SYNAPSE (IS)
A. Mechanism of Formation of IS
T-cell activation is initiated upon interaction of antigen-presenting cells (APC) with T cells 
via major histocompatibility complex (MHC) and T-cell receptors (TCR) for generating 
adaptive immune response.1,2 Monks et al. were the first to report the formation of a three-
dimensional cell–cell contact between a fixed single T cell and an antigen-presenting cell 
(APC).3 This cell–cell contact is an interaction of surface receptors and intracellular proteins 
in a well-organized and spatially distributed manner, leading to the formation of two 
concentric rings termed “supramolecular activation clusters” (SMAC). The inner ring is 
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referred as the central TCR-SMAC (c-SMAC or Signal-1). It is composed of protein kinase 
C (PKC-θ) surrounded by an outer or peripheral SMAC (p-SMAC or Signal-2) enriched 
mainly with leukocyte function-associated antigen-1 (LFA-1) and talin. Initial contact 
between the T cell and APC involving TCR and MHC–peptide (MHC–p) and other 
costimulatory molecules is called the “immunological synapse” (IS).4 Grakoui et al. have 
shown that the formation of a nascent IS is initiated by Signal-2 (i.e., intercellular adhesion 
molecule-1 (ICAM-1) and LFA-1 interactions) at the central junction and by Signal-1 
(TCR–MHC–p interactions) at the peripheral junction of the interface between APC and T 
cells.5 Signal-1 and Signal-2 then exchange places (translocate) via actin-based movement 
to form a stable Signal-1 cluster at the center and a Signal-2 cluster at the peripheral junction 
(Fig. 1).
Many costimulatory molecules (Signal-2) have been discovered, including CD28/B7-1 
(CD80) and CD28/B7-2 (CD86) as positive costimulatory signals and cytotoxic T 
lymphocyte antigen (CTLA-4)/B7-1 and CTLA-4/B7-2 as negative costimulatory signals 
(Fig. 2).6–8 The cytoskeletal protein talin and CD2-associated protein as well as intracellular 
signaling proteins, such as PKC-θ, LcK, ZAP, Fyn, and MEKK2, have also been 
identified.8,9 The roles of negative and positive costimulatory signals are to maintain the 
balance between the regulatory and effector functions of T cells in the immune system.
The structure and function of IS are still not well understood because the formation of a 
mature IS occurs via a dynamic process. In other words, the formation of a mature IS is not 
merely the formation of protein clusters to sustain TCR signaling; it also requires the 
involvement of TCR-mediated tyrosine kinase signaling before IS maturation.10,11 This 
suggests that the process of IS formation could be preceded by T-cell activation10,11 and 
possibly the secretion of cytokines or cytotoxic agents by CD4+ and CD8+ T cells, 
respectively, upon interaction with APC.11–16 The IS enhances the interaction of CD28/
B7-1/2 at the center.11 Lezzi et al.17 demonstrated that the activation and deletion of either 
naïve or effector T cells is dependent on the duration of antigenic stimulation. Prolonged 
antigenic stimulation is required for the activation of naïve T cells, but it causes apoptosis in 
effector T cells. Celli et al. found that more than 6 hr interaction between naïve CD4+ T cells 
and dendritic cells (DC) is necessary to produce T-cell clonal expansion and inhibition of 
TCR-MHC interactions that stops the T cell–DC interactions.18 Furthermore, TCR 
clustering enhances binding with MHC–p, and the cSMAC is an important site for strong 
TCR signaling.19,20 The internalization of TCR is required for downregulation of TCR 
signaling.19 The formation of IS may be required for gene activation to induce and secrete 
effector molecules and for intercellular transfer of MHC–p complex along with other 
receptors such as B7-1 from APC to T cell.8,21,22 This event may have biological 
repercussions, allowing T cells to behave as APC, altering the cellular functions and over all 
controlling the immune response itself.23
B. Signal-1
A complex of an immunogenic peptide and purified MHC-II (Ia) molecule is recognized by 
the TCR as a model for Signal-1,24,25 and the antigen presentations by MHC-I- or CD1 
MHC-like molecules have been described previously.26–30 These findings were further 
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confirmed by solving various crystal structures of peptide–MHC complexes.31–39 Later, the 
specific TCR recognition of MHC–p complex on the surface of APC as a result of antigen 
processing was termed as Signal-1.40,41 TCR consists of an α/β or γ/δ heterodimer 
connected via a disulfide bond with one variable and one constant region at the extracellular 
domain.42 The variable domain has the greatest diversity as a complementary-determining 
region 3 (CDR3).43 The sequence of CDR3 is primarily involved in recognizing the 
antigenic peptide presented by MHC molecules on APC.44 MHC class I and class II 
molecules on APC bind antigenic peptides derived from endogenous and exogenous 
proteins, respectively. Lipid antigens captured from exogenous antigens bind to CD1 MHC-
like molecules.30,45
Upon activation, T cells can differentiate into TH1, TH2, and TH17 cells. TH1 cells produces 
cytokines such as IFN-γ and lymphotoxin.4,46 TH2 cells produce IL-4, IL-13, IL-5, and IL-6 
cytokines,4,14,46 and TH17 cells generate IL-17.47 Naïve CD4+ T cells can also be 
differentiated into an independent lineage called regulatory T cells (Treg), which express 
fork-head transcription factor Foxp3 and CD25.47 CD4+ T cells execute many important 
effector functions, depending on the cytokines they secrete.46 Treg cells are also produced 
and primed with antigen in the thymus as part of mature cells for controlling immune 
response.48 CD8+ T cells are capable of differentiating into cytotoxic T lymphocytes 
(CTL);12 these cells recognize specific antigens presented by MHC class-I on their target 
cells and perform cell lyses.13,15
There are varieties of MHC-II (polymorphic) expressed on the surface of professional APC 
(pAPC) (i.e., B cells, DC, and macrophages). MHC-II molecules are generated as 
heterodimers (α- and β-chains) with α1–α2 and β1–β2 domains at the extracellular space.35 
The α1- and β1-domains bind to the antigenic peptide for presentation to TCR.49 Except for 
the α1 domain of MHC-II, all other extracellular domains possess an intradomain disulfide 
bond. The transmembrane and cytoplasmic domains of MHC-II posses specific sequences 
required for efficient surface expression,50 signaling,51 antigen presentation,52,53 and lateral 
diffusion of MHC-II molecules on the surface of the APC.54
The antigens can be processed and presented by different APC in different ways. For 
example, the antigen presentation by MHC-II on DC is more effective for activating naïve T 
cells than that by B cells.55 Before the presentation of the peptide fragments of the antigen, 
the antigen is first internalized via phagocytosis, fluid-phase uptake by macropinocytosis, or 
receptor-mediated endocytosis via mannose and lectin-like receptors.56–58 Then, they are 
processed via early endosome and then transferred to late endosome before entering 
lysosomes.59–63 Because MHC-II compartments (MIIC) are rich in lysosomal enzymes, 
proteins are degraded by lysosomal proteases to generate peptide fragments; these peptides 
are loaded onto MHC-II molecules in the MIIC.64–66 The new MHC-II molecules are 
synthesized and assembled with invariant chain (Ii) in the endoplasmic reticulum to form 
MHC-II–Ii complexes, which are then transported to the Golgi apparatus and targeted to the 
endosomal/lysosomal compartments.67–70 The portion of Ii in MHC-II–Ii complex is then 
clipped off by proteases to produce MHC-II molecules with class II-associated invariant 
chain (CLIP). Then, the CLIP is exchanged for antigenic peptide to form the MHC-II–
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peptide (MHC-II–p) complex that is transported to the surface of the APC for presentation 
to a CD4+ T cell.28,66
C. Signal-2
Several roles of costimulatory signals (Signal-2) are to stabilize the physical interactions 
between TCR and MHC as well as modulating the TCR signal for T-cell activation and 
tolerance.71,72 The positive and negative costimulatory signals can be delivered by CD28/B7 
and CTLA-4/B7 interactions (Fig. 2), respectively.73–75 Human CD4+ T cells and half of 
CD8+ T cells express CD28 with a possible increase in expression upon T-cell 
activation.76,77 A combination of TCR signaling and costimulation via CD2/B7 pathway can 
upregulate the production of IL-12 receptor,78–81 Bcl-χL,82 and cytokine transcription.83,84 
Suppression of the positive costimulatory signal in the presence of TCR–MHC-II–antigen 
complex generates T-cell anergy, which can be reversed by delivering IL-12.85,86 Large and 
small molecules have been designed to block CD28/B7 signals for therapeutic agents to 
suppress autoimmune diseases. Therefore, it is necessary to balance the positive 
costimulatory signal with the negative costimulatory signal (CTLA-4/B7) to maintain 
tolerance. Normally, CTLA-4 is expressed in activated but not in resting T cells to dampen 
signals delivered via TCR. CTLA-4 expression is observed at 24–48 hr after priming,87 and 
the strength of expression correlates with stimulus by TCR88 upon recruiting Src homology 
2 (SH2) domain-containing phosphatase-2 (SHP-2) during T-cell activation.89
APC normally express B7-1 (CD80) and B7-2 (CD86); these proteins have V- and C-like 
domains as well as cytoplasmic domains with phosphorylation sequences for PKC 
recognition.75,90–93 B7-1 and -2 can be upregulated upon activation,94 and they are 
recognized in lower avidity by CD28 than by CTLA-4.95,96 Both CD28 and CTLA-4 have a 
MYPPPY motif that is recognized as the extracellular V-like and C-type domains of B7-1 
and -2.95,96
Inducible costimulator (ICOS) and programmed death-1 (PD-1) molecules are additional 
types of costimulatory molecules in the CD28 family. ICOS has a FDPPPF motif rather than 
a MYPPPY motif in the CD28 molecule; owing to the different in this recognition sequence, 
ICOS does not bind to B7-1 and B7-2.97,98 However, ICOS binds to B7-h molecule upon 
stimulation by TCR activation to increase T-cell proliferation97,99–101 as well as IL-4, IL-5, 
IFN-γ, TNF-α, and GM-CSF production.100 B7-h also regulates the production of IL-10 and 
plays a role in induction of tolerance.102,103 B cells and macrophages constitutively express 
B7-h, and its expression can be induced by inflammatory stimuli on fibroblasts as well as 
nonlymphoid, endothelial, and epithelial cells.
In addition to CTLA-4, PD-1 can deliver negative signals in CD8+ T cells to generate 
tolerance, and both CTLA-4 and PD-1 signals work in an additive fashion upon sustained 
connection with their respective ligands.104 The ligands for PD-1 are PD-L1 (B7-H1) (Fig. 
2) and PD-L2 (B7-DC).104 PD-L1 is widely expressed on T cells, B cells, macrophages, 
monocytes, DCs, and nonlymphoid cells, including endothelial cells, syncytiotrophoblasts in 
the placenta, muscles, and pancreatic islets,105 whereas PD-L2 is only found on 
macrophages and DCs inducible by cytokines.106 The PD-1 molecule has roles in induction 
and/or maintenance of peripheral tolerance and acts as a negative regulator of T-cell 
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responses. Mice with PD-1 deficiency developed a fatal dilated cardiomyopathy with early 
disease onset107 and lupus-like disease.104 PD-1 is expressed during thymic development 
primarily on CD4− CD28− and γ−δ− thymocytes and induced on peripheral CD4+ and CD8+ 
T cells, B cells, and monocytes upon TCR stimulation.105 Unlike CTLA-4, PD-1 inhibits the 
expression of the cell survival gene bcl-XL,105 and both CTLA-4 and PD-1 are known to 
limit glucose metabolism and Akt activation via different pathways. CTLA-4 inhibits Akt 
activation via protein phosphatase 2a, and PD-1 inhibits Akt activation via CD28-mediated 
activation of PI3K. Blocking CTLA-4 with antibody reduces CD8+ T-cell tolerance upon 
epitope presentation by resting DC; however, blocking CTLA-4 signal in the presence of 
PD-1 signal produces weak but constant T-cell priming.104
LFA-1 and ICAM-1 function as both adhesion and costimulatory molecules (Fig. 2) for T-
cell activation.108 Functionally, LFA-1 has been shown to enhance IL-2 expression, leading 
to the induction of T-cell proliferation. LFA-1 is exclusively expressed on leukocytes and 
interacts with its ligands, such as ICAM-1, -2, and –3, to promote a variety of homotypic 
and heterotypic cell–cell adhesion necessary for normal and pathologic functions of the 
immune systems. The interaction of LFA-1 with its ligands allows for improved adhesion of 
leukocytes to vascular endothelium, an essential step in the recruitment and migration of 
leukocytes into inflamed tissue.109–111 Similarly, LFA-1-mediated adhesion is thought to 
facilitate antigen presentation to T cells, and numerous reports indicate that LFA-1 
engagement decreases the minimal stimulatory dose of antigen by 10- to 100-fold.112–114
D. Signal-3
Signal-3, which is provided by the release of inflammatory cytokines by APC or T cells 
after initiation of Signal-1 and -2, is required for proliferation and differentiation of T 
cells.115,116 Signal-3 can polarize helper T cells to become type 1 helper T cells (TH1) or 
type 2 helper T cells (TH2).117 The “danger theory” proposed by Matzinger indicated that T 
cells must receive the “danger signal” from Signal-3 and costimulatory signals for their full 
activation to recognize the danger from pathogens.118,119 In contrast, in the absence of the 
“danger signal,” the immune system induces tolerance instead of an immunizing effect. To 
determine the effect of the “danger signal” on CD8+ and CD4+ T-cell proliferation, Mescher 
et al. utilized microspheres coated with immobilized MHC protein/peptide complexes 
(artificial APC) to provide Signal-1 and co-immobilized with B7-1 protein for Signal-2.115 
IL-12 as Signal-3 was needed along with Signal-1 and -2 to stimulate and proliferate naïve 
CD8+ T cells and, in the absence of IL-12, the T cells did not differentiate into cytolytic 
effector cells. Similarly, IL-1 but not IL-12 was necessary to proliferate naïve CD4+ T cells. 
These results suggest that Signal-3 from inflammatory cytokines is necessary for 
proliferation of CD4+ and CD8+ T cells to prevent tolerance toward a specific antigen.
As a “polarizing” signal, Signal-3 is delivered to naïve helper T cells for their differentiation 
to either TH1 or TH2, and the differentiation depends on the type of cytokine delivered as the 
Signal-3. If the naïve helper T cells receive IL-12 signal, they differentiate into TH1. If they 
receive IL-4, the helper T cells differentiate into TH2.117 TH1 cells can produce interferon-γ 
(IFN-γ) and tumor necrosis factor-α (TNF-α) for directing T-cell immunity against 
intracellular pathogens. TH2 cells produce IL-4, IL-5, and IL-13 for optimal self-
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proliferation to control humoral immunity as well as fighting against extracellular parasites. 
The generation of Signal-1 and Signal-2 triggers signal transductions via several different 
pathways, including calcium–calcineurin, the RAS-mitogen-activated protein (MAP) kinase, 
and the nuclear factory-κB pathways (Fig. 2).116,120 IL-2 binds to IL-2 receptor (IL-2R) on 
T cells along with other cytokines to initiate T-cell proliferation through the rapamycin 
pathway.116 The mechanisms of action of cytokines in triggering the appropriate CD4+ and 
CD8+ T-cell responses are still not clear and need further investigation.115
2. ANTIGENIC PEPTIDES
Autoimmune diseases could involve a single organ (e.g., multiple sclerosis (MS), 
rheumatoid arthritis (RA), and diabetes) or no involvement of specific organs (e.g., systemic 
lupus erythematosus). T cells and B cells are engaged in inflammatory immune responses, 
leading to the onset and progression of autoimmune diseases. Activation of both T and B 
cells depends on antigen presentation. Although antigens are necessary for activation of 
these lymphocytes, several studies have shown that injections of antigenic peptides/proteins 
could also suppress autoimmune diseases. The mechanisms of suppression by antigens are 
thought to work by immune deviation and induction of Treg cells. In the following sections, 
etiologies and current treatments of various autoimmune diseases are discussed.
A. Multiple Sclerosis
MS is an autoimmune disease that affects the central nervous system; patients suffer from 
muscle weakness, changes in sensation and speech, vision problems, muscle spasms, and 
fatigue. In this disease, the autoreactive immune cells (i.e., T cells) attack and cause damage 
to the axonal via demyelination and inflammation.121 The myelin sheath damage hampers 
the communication between nerve cells due to the disruption of the electric impulses along 
the axons and affects the optic nerves, brainstem, spinal cord, cerebellum, and 
periventricular white matter. As the result of oligodendrocyte cell death and loss of axons, 
plaques and lesions can be observed in the brain white matter as well as in the spinal cord. 
This is a pathological marker of MS.
Nearly 80% of MS patients have clinical relapses referred to as relapsing–remitting MS 
(RRMS), which is characterized by inflammation of the brain and spinal cord along with 
white matter lesions.122 During the RRMS period, patients have unpredictable relapses 
followed by long remission with no signs and symptoms of the disease; about 65% of these 
patients will gradually progress toward a secondary progressive MS (SPMS) typified by an 
irreversible neurological defect.122 Some patients (20%) have a steady neurological decline 
without remission upon onset of the disease, which is called primary progressive MS 
(PPMS); however, PPMS is the least common type of MS. Axonal degeneration due to the 
loss of myelin sheath is commonly observed in PPMS and SPMS.
The cause of MS has not been fully elucidated; however, it is clear that MS patients have a 
leaky blood–brain barrier (BBB) with brain infiltrations of CD4+/CD8+ T cells, B cells, and 
monocytes.121,123,124 There is evidence to indicate that proteolipid protein (PLP), myelin 
basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), or some peptide 
epitopes from these proteins act as self-antigens for T-cell activation (Table I). In the CNS, 
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naïve CD4+ T cells recognize the antigen presented by the local APC called microglia and 
they differentiate to TH1 effector cells, which produce IL-2, IFN-γ, and TNF-α.125 In 
addition, TH17 cells that secrete IL-17 cytokine are also activated by IL-6, IL-23, and TGF-
β.126,127 Thus, MS patients have elevated levels of IL-17 in the blood and cerebrospinal 
fluid (CSF).128,129 It has been suggested that the BBB of MS patients is leaky and that IL-17 
and -22 are responsible for the disruption of the BBB that aids the CNS infiltration of 
immune cells.122 Injection of anti-IL-17 monoclonal antibody (mAb) into SJL/J mice with 
autoimmune encephalomyelitis (EAE) suppresses the disease development, indicating that 
IL-17 has an important role in the pathogenesis of EAE and possibly MS.127,130 Contrary to 
this proposal, Haak et al. indicated that IL-17 may not be the major player in pathogenesis of 
EAE in mouse because IL-17F-deficient mice treated with anti-IL-17 mAb can still develop 
EAE.131 Their study indicated that IL-17 may not have a critical role in the pathogenic 
function of TH17 cells and TH1 cells are necessary to initiate CNS inflammation followed 
by CNS infiltration by TH17 cells.131 Haak et al. suggested that although eliminating IL-17 
may not be a viable target for treating MS, it is still a good diagnostic marker for MS.131
Treatment of animal models of EAE with soluble myelin antigens can generate tolerance in 
diseased animals. For example, oral administration of MBP to Lewis rats before the EAE 
induction suppresses EAE as a result of clonal anergy or deletion of activated T cells with a 
reduced number of TH1 MBP-specific cells.132–135 Administration of bovine myelin 
antigens in a small group of MS patients provided a significant decrease in the number of T 
cells reactive toward MBP compared with the control group and a lower number of treated 
patients showing major attacks compared with the untreated control group.136 
Unfortunately, a subsequent large clinical trial (Phase III) did not show the efficacy of a 
single oral dose of myelin antigens (MBP and PLP); the previous effects were considered to 
be a placebo effect. Thus, there are many unanswered questions about the effectiveness of 
this type of treatment.
Alternatively, intrathecal, intravenous (i.v.), subcutaneous (s.c.), or nasal administration of 
antigenic peptides has been investigated to induce tolerance in patients. Two phase I trials 
conducted by Warren et al. demonstrated that administration of MBP peptides, MBP75–95 or 
MBP85–96, in chronic progressive MS patients did not produce any adverse effects.137,138 
Induction of tolerance was monitored by detecting the reduction of anti-MBP antibodies in 
CSF. Intrathecal administration resulted in transient neutralization, whereas i.v. 
administration resulted in long-lasting tolerance or reduction in anti-MBP antibodies for up 
to 1 year after a second i.v. dose of antigen. However, s.c. administration of the antigenic 
peptides did not affect the reduction of anti-MBP antibodies in CSF, clearly demonstrating 
that s.c. injection failed to induce tolerance in these patients.138 Unfortunately, these studies 
failed to relate the clinical significance of the reduction in antibodies against MBP and its 
effect on the prognosis of the disease in MS patients.
Antigenic peptides derived from MBP were successfully delivered via the nasal route and 
were effective in inhibiting EAE disease in a murine model.139–142 It has been suggested 
that proliferation of antigen-specific Treg cells in EAE can be triggered by antigenic-peptide 
presentation by plasmacytoid dendritic cells (pDC) as part of the professional APC.143 The 
mechanism of tolerance in this model is due to MBP-reactive specific Treg cells that produce 
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IL-10. In addition, these cells were found to express higher levels of IL-4 and TGF-β 
mRNA.141,144 Similarly, altered peptide ligands (APL) are mutated antigenic peptides with 
increased affinity for MHC-II and/or TCR, and they have been shown to control RA and 
EAE in animal models. A suggested mechanism of action for APL in inhibiting antigen-
specific T-cell activation is increasing the expression of indoleamine 2, 3-dioxygenase 
(IDO) enzyme in activated T cells. Presumably, the increased amount of IDO converts 
tryptophan to its metabolites (i.e., 3-hydroxykynurenic acid (3-HKA), picolinic acid (PA), 
and quinolinic acid (QA)) and these metabolites suppress the EAE relapse by reducing the 
production of inflammatory cytokines and stimulating the production of IL-4 and IL-10 that 
are related to TH2 and Treg cellular differentiation.145
Another promising approach developed for the treatment of MS involves the use of 
recombinant T-cell ligands (RTL). A human recombinant T-cell receptor ligand (RTL1000) 
consisting of DR2 α1+β1 domains of MHC-II molecules linked covalently to MOG35–55 
peptide was shown to reverse clinical and histological signs of EAE146 and was evaluated 
for safety in a phase 1 randomized, placebo-controlled, escalating dose study in 34 patients 
with MS.147 Preclinical studies of RTL showed that these molecules were effective in 
ameliorating both active and passive MOG-induced EAE in C57BL/6 mice146 and chronic 
EAE in SJL/J mice.148 One of the constructs, RTL401 (RTL with bound PLP139–151), was 
able to suppress EAE in SJL/J mice immunized with PLP139–151 but could not treat 
MOG35–55-induced EAE.148 Furthermore, RTL401 could not treat EAE in mice immunized 
singly with PLP178–191 or MBP84–104 peptides, and the same was also true with other RTL 
constructs linked to different peptides.148 This suggests antigen-specific suppression of EAE 
by RTL modulation of the cognate T-cell specificity. Interestingly, RTL401 was able to 
ameliorate EAE induced with syngenic whole spinal cord homogenate, indicating that 
treatment with a single RTL can suppress EAE induced with multiple T-cell specificities 
provided that one of the immunizing peptides is present in the RTL being used for treatment. 
This demonstrates that treatment with a single RTL can deviate autoimmune responses of 
cognate T-cell specificities while inducing bystander suppression that reverses EAE in mice 
immunized with multiple encephalitogenic peptides.148 It is thought that the mechanism of 
action of RTL involves direct reduction of proinflammatory cytokines, such as IL-17 and 
TNF-α, while concomitantly inducing the production of IL-10, IL-13, and TGF-β and 
inhibiting the migration of inflammatory cells into the CNS via a reduction in the expression 
of chemokines/receptors, VCAM-1, and ICAM-1.146,148
Current strategies that are approved for the treatment of MS include two classes of drugs: 
anti-inflammatory and disease-modifying therapies (DMT). Acute MS relapses are often 
treated with high-doses of intravenous corticosteroids such as methylprednisolone. This is 
effective for short-term treatment, but it does not have any effect on long-term recovery. 
Mitoxantrone (Novantrone®), interferon β-1a (IFNβ-1a or Avonex®/Rebif®/CinnoVex®), 
IFNβ-1b (marketed as Betaseron®/Betaferon®), glatiramer acetate (GA, Copaxone®), and 
natalizumab (Tysabri®) are current DMT drugs. Mitoxantrone will not cure the disease, but 
it is effective in slowing the progression of SPMS and delaying the relapse interval time in 
RRMS.149 The mechanism of action of mitoxantrone involves disrupting both DNA 
synthesis and DNA repair. The side effects of mitoxantrone are irreversible cardiomyopathy, 
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acute leukemia, and bone-marrow suppression; patients receiving this treatment are advised 
to have regular echocardiograms.
IFNβ-1b was first introduced in 1993 for RRMS treatment. In the clinical trials, patients 
treated with IFNβ-1b were free from relapse at the end of 2 years compared with a placebo-
treated group.150 IFNβ-1b acts as an anti-inflammatory agent by reducing the production of 
IFN-γ and TNF-α and inhibits T-cell activation, clonal expansion, and migration into the 
CNS.151 The mechanism of action of IFNβ-1a is thought to be similar to that of IFNβ-1b.
Copaxone® (glatiramer acetate) is a synthetic peptide polymer (40–100 residues) that 
consists of Glu, Lys, Ala, and Tyr amino acids in a ratio of 3:7:9:2; it is designed as a decoy 
for MBP. Copaxone® has been suggested to alter the immune response from TH1- to TH2-
cell differentiation.
Finally, natalizumab (Tysabri®) is the first recombinant human mAb approved for the 
treatment of MS. It inhibits leukocyte adhesion to vascular endothelium by binding to the 
α4-subunit of α4β1 and α4β7 integrins on the surface of leukocytes to prevent leukocyte 
infiltration into the CNS.152 Natalizumab has been shown to significantly slow the progress 
of disability with increasing numbers of disease-free individuals compared with placebo 
group. It can also reduce disease relapse, loss of vision, and number of lesions in 
patients.153–155 Despite its greater efficacy compared with any other approved MS therapies, 
its use is limited because of the development of potential fatal adverse effects, such as 
progressive multifocal leukoencephalopathy (PML), melanoma, hepatotoxicity, 
opportunistic infections, and primary CNS lymphoma.156,157 Recent studies suggest that 
patients receiving this drug for more than 1 year are at an increased risk for PML.158 
Currently, the FDA has limited the usage of natalizumab to patients not responding to other 
therapies, and the drug is under a mandatory safety monitoring program.
B. Type-1 Diabetes
Type 1 diabetes (T1D) is marked by insulitis and the destruction of the pancreatic islet of 
Langerhans β cells.159 Although not all-inclusive, studies carried out in nonobese diabetic 
(NOD) mice show that CD4+ and CD8+ T cells are partly responsible for the destruction of 
the β-cells.7 Those afflicted with T1D are genetically predisposed, and the progress toward 
the disease is initiated after encountering an environmental insult, such as diet or microbial 
infections.7 Insulin, glutamic acid decarboxylase (GAD), zinc transporter (ZNT8), and 
insulinoma antigen (IA-2) are the four major antigens (Table I) for activation of immune 
cells, and they have been used in assays to detect the progress of T1D.160,161 Glutamic acid 
carboxylase 65 kDa (GAD65) is considered a target for therapy because of its partial role in 
the activation of certain T cells that recognize it as an antigen.159
The immunotherapy of T1D focuses on two alternative methods of treatment: prevention of 
T1D or treating it at its onset. Ever since its discovery, insulin has been considered to be the 
gold standard of treatment for patients with Type 1 diabetes. Similar to GAD65,159 insulin 
has also received attention as a therapeutic method to suppress the activation of T cells.161 
By suppressing the activation of T cells, β-cells may be regenerated, and this may lead to the 
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remission of diabetes.7 The administration of autoantigens (GAD65 or insulin) and their 
peptides has been shown to suppress β-cell autoimmunity.7,159
The role of insulin as an autoantigen is still ambiguous. To date, many epitopes of insulin 
and proinsulin have been identified.161 Recent findings have shown that insulin auto-
antibodies can be induced by insulin B9–23 peptide. NOD mice (H-2d) were immunized 
with B9–23 peptides, which led to the development of MHC-activated autoantibodies 
toward insulin.162 However, it has been shown that the antibodies toward insulin react only 
with insulin and not with NOD B9-23 peptides, suggesting that insulin antibodies recognize 
the whole molecule rather than the peptide sequence itself.161 Proinsulin, the precursor of 
insulin, also has a sequence of amino acids (B24–C36) that are recognized by NOD mice 
CD4+ T cells.163 B9–23 has been hypothesized to play an important role in humans as it did 
in NOD mice because the amino acid sequences are similar in both species. Higashide et al. 
have shown that the most frequent epitopes recognized by T cells are B10–24, B1–15, and 
B11–25, with B9–23, B4–18, and B12–26 being identified in some patients.164 
Alternatively, it has been observed in NOD that intranasal vaccines containing proinsulin in 
a plasmid DNA increased the number of Treg cells and effectively prevented the onset of 
diabetes.165
GAD65 is an enzyme that is targeted as an autoantigen by T cells. Anti-GAD65 antibodies 
can be observed in NOD mice before the onset of T1D. Injection of GAD65, intravenously 
or intrathymically, to young NOD female mice before any signs of disease has been shown 
to prevent diabetes and induce CD4+ Treg cells.166 Controlling the activation and increasing 
the induction of Treg cells by GAD65 antigen may help to suppress T1D.159 Tisch et al. 
revealed that peptides derived from GAD65 are able to suppress the progression of T1D in 
NOD mice before the onset of insulitis. The peptides used include amino acids 217–236, 
247–265, 290–309, and 524–543.167
C. Rheumatoid Arthritis
RA is a chronic idiopathic disease characterized by persistent inflammation and local 
destruction in the synovial tissues including the synovium, bone, and cartilage. Although the 
nature of the antigens responsible for RA pathogenesis has not been clearly elucidated, there 
is evidence that the disease-associated HLA DR (B1*0401, 0404, 0405, and 0101) 
molecules, which reside in the MHC and participate in antigen presentation, are associated 
with the disease.168 Viral proteins, such as cytomegalovirus and Epstein-Barr virus, as well 
as several autologous proteins normally expressed in the joints, including gp39, 
proteoglycan, and type II collagen, have been implicated in the generation of the pathogenic 
T-cell response in RA (Table I). The driving force behind rheumatoid inflammation is 
believed to be CD4+ T cells responding to an antigenic epitope in the synovium in an HLA-
DR-restricted manner. Increased numbers of “memory” CD4+ and decreased numbers of 
“naïve” CD4+ T cells in the synovial tissues of RA patients169,170 suggest that CD4+ T cells 
play a crucial role in the pathogenesis of RA. Synovial tissue T cells are enriched with CD4+ 
T cells that do not express the Leu 8 antigen, now known to be the human equivalent of the 
murine homing receptor.171–173 Loss of this molecule is a characteristic of activated T cells. 
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Synovial fluid also contains augmented expression of the activated antigens HLA-DR, CD9, 
CD38, CD49a/CD29 (VLA-1), and adhesion molecule CD54 (ICAM-1).174–177
In addition to CD4+ T cells, a number of other inflammatory mediators produced in the 
rheumatoid synovium, including arachidonic acid metabolites, vasoactive amines, platelet-
activating factor, and complement cleavage products, contribute to the inflammation. 
Recently, IL-17 produced primarily by the TH17 cells has also been implicated in human 
autoimmune inflammation. A potential key role in diseases such as RA has only recently 
been attributed to IL-17, although it was discovered decades ago. Elevated levels of IL-17 in 
blood and synovium of RA patients have been correlated with synovial levels and joint 
damage.178–180 Recent advancement in research toward new and better-tolerated therapies 
to attenuate the inflammation and pain associated with RA as well as halt the progression of 
erosive joint damage has led to the development of strategies for modulating stimulation of 
immune cells or blocking cytokines as potential therapeutic strategies.
Injections of soluble antigens have been shown to induce antigen-specific immune tolerance. 
It is thought that tolerance could be achieved through anergy/deletion of CD4+ T cells or the 
induction of CD4+ Treg cells that produce IL-10 or TGF-β.181 Oral, and more recently nasal, 
tolerance resulting from administration of antigens has attracted attention as a potential 
treatment of autoimmune diseases. Oral administration of type II collagen (CII) has been 
shown to suppress arthritis in mice182 and rats.183 Oral administration of chicken CII to 
patients with RA provided significantly less progression of the disease compared with 
placebo-treated patients.184
In another study, peripheral blood mononuclear cells of RA patients responded well in vitro 
to CII256–271 epitope and its overlapping variants.185 Similarly, oral administration of this 
peptide has been shown to suppress arthritis in a CIA mouse model.185 Specific T-cell 
activity, proliferation, and secretion of IFN-γ in spleen cells were actively suppressed in 
CII250–270-fed mice, and the serum anti-CII, anti-CII250–270 antibody activities and 
frequency of specific antibody-forming spleen cells were significantly lower in CII250–270-
fed mice than in controls. Moreover, IL-4-producing cells (TH2 cells) were upregulated 
when CIA mice were treated with type II collagen (CII250–270), suggesting that oral 
administration of CII250–270 can suppress the cellular and humoral immune response in 
collagen-induced arthritis. Although the majority of animal studies have yielded positive 
results with the oral tolerance regimen, under some circumstances, mucosal application of 
antigen may instead exacerbate the disease process.186
Therapeutic effects of murine MHC class II (I-Aq)-derived recombinant T-cell receptor 
ligands (RTL), consisting of the α1 and β1 domains of MHC class II molecules that are 
covalently linked to the CII immunodominant peptide (CII257–270), were also found to 
reduce the incidence and clinical and histological signs of CIA.187 Treatment with RTL 
resulted in increased CII-specific IgG1and a reduction in IgG2a isotype that is normally 
associated with a pathogenic response. The mechanism of RTL in CIA appears to be, due to 
an increased expression of the FoxP3 gene, an upregulation in anti-inflammatory cytokines 
(IL-10 and IL-13) and a downregulation in proinflammatory cytokines (IL-17 and IFN-
γ).187
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Abatacept, also known as CTLA4-Ig, was approved in 2005 by the FDA for the treatment of 
patients with moderate-to-severe active RA who have had an inadequate response to 
disease-modifying antirheumatic drugs (DMARDS), including methotrexate (MTX) and 
TNF antagonists. It is a fusion protein composed of the extracellular domain of the CTLA4 
molecule complexed to the Fc domain of human IgG1. The IgG1 solubilizes the fusion 
protein; thus, unlike the membrane-bound CTLA4 molecule, its binding to CD80/CD86 
does not induce a negative signal to T cells. Its binding blocks the engagement of the CD28 
costimulatory signal required for T-cell activation, resulting in T-cell anergy.188 Patients 
receiving abatacept responded better than those receiving placebo. Quality of life was also 
improved with abatacept and benefits were sustained at 12 months, these included 
significant reduction in disease activity as well as improved physical function.189
Infliximab is a chimeric monoclonal antibody that binds to circulating and transmembrane 
TNF-α and thereby neutralizes its biological effect. Circulating TNF-α is a form of TNF-α 
generated by cleavage from the transmembrane precursor. Both forms of TNF-α have been 
shown to sustain the inflammation process. Transgenic mice overexpressing TNF-α were 
observed to develop a destructive arthritis resembling RA. Moreover, high levels of TNF-α 
detected in synovial fluid and in the tissues of patients with RA190 suggest that TNF-α plays 
a pivotal role in physiologic and pathogenic response.191 In addition to infliximab, a number 
of agents that block TNF-α have been developed for clinical use, including etanercept, 
adalimumab, and certolizumab. Etanercept is a conjugate between a human TNF-α receptor 
and the Fc-portion of the human IgG1. Adalimumab is a recombinant human IgG1 
monoclonal antibody specific for TNF-α; it not only inhibits binding of TNF-α to its 
receptors but also lyses cells expressing membrane-bound TNF-α. Certolizumab, on the 
other hand, is a polyethylene glycol (PEG)-conjugated humanized anti-TNF Fab fragment. 
Although anti-TNF-α drugs have been shown to be effective and relatively safe for use in 
treating RA, blockade of this cytokine may have effects beyond the suppression of synovial 
inflammation, which can influence mortality of these patients. Mycobacterial infections 
have been reported among patients undergoing therapy with infliximab.192,193 Therefore, 
tuberculin skin tests and a chest radiograph are usually recommended before initiation of 
anti-TNF treatment. Also, avoidance of anti-TNF therapy is recommended for patients with 
severe chronic heart failure.194 Aside from TNF-α, cytokines appear to be of particular 
importance in the development of RA and, therefore, have been investigated as therapeutic 
targets. Kineret (Anakinra) is a recombinant, non-glycosylated form of the IL-1 receptor 
antagonist (IL-1Ra), a naturally occurring receptor antagonist known to counteract the 
proinflammatory effects of interleukins. Patients taking background MTX with anakinra had 
significant clinical improvement as compared with the placebo group.195,196 Simultaneous 
blockade of TNF-α and IL-1 receptor had very promising results in experimental murine 
arthritis;197 however, this did not translate well to clinical outcome. Moreover, the risk of 
mycobacterial infections under combination therapy increased significantly; it is therefore 
not recommended for RA treatment.198 Tocilizumab (MRA) is a humanized monoclonal 
antibody against IL-6 receptor (IL-6R). Randomized phase II studies showed that patients 
receiving tocilizumab had reduced disease activity in a dose-dependent manner.
B lymphocytes play several critical roles in the pathogenesis of RA. They are the source of 
rheumatoid factors and anticitrullinated protein antibodies, which contribute to the immune 
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complex and complement of T-cell activation in the joints. It is therefore assumed that the 
depletion of B lymphocytes provides a potential therapeutic approach to controlling disease 
activity and inducing remission. This hypothesis has been proven in an open-label study of 
rituximab, a chimeric monoclonal antibody against the protein CD20. CD20 is widely 
expressed on B cells from early pre-B-cells to later stages in differentiation, but it is absent 
on terminally differentiated plasma cells. Rituximab was significantly superior to placebo 
when added to MTX.199 Safety and tolerability of rituximab were found to be comparable to 
that of the placebo. Moreover, there have been no higher infection rates under B-cell 
depletion therapy.199
3. BLOCKING SIGNAL-2
Blocking Signal-2 formation has been shown to alter the immune response via induction or 
anergy of a certain T-cell phenotype (i.e., TH1 or TH2). Inhibition of Signal-2 has been used 
for the treatment of autoimmune diseases. Monoclonal antibodies and peptides (Table II) 
that inhibit Signal-2 have been shown to suppress allograft rejection,200,201 type-1-
diabetes,202,203 RA,204,205 and psoriasis.206,207 Despite the great promise of mAb, these 
drugs are costly to produce and difficult to formulate or deliver. Peptides and 
peptidomimetics are a better alternative to mAbs. Despite progress in designing small 
molecule inhibitors, a limited number of small molecules have been designed to target 
Signal-2, but none has yet reached the clinical setting.
A. LFA-1/ICAM-1 Interaction
Studies performed in vivo and in vitro have demonstrated that T-cell activation requires 
interaction of adhesion receptors. Initially, when T cell, encounter APC, adhesion receptors 
physically anchor and provide feedback to the T cells about the surface milieu of the APC. 
This may indeed be followed by TCR signaling and tightening of the distance between the 
two membranes through translocation of the receptors.8,208 Adhesion receptors such as 
ICAM-1 are considered to be involved in intracellular signaling, leading to the accumulation 
of the immune receptors along with MHC molecules at the contact area for the efficient 
presentation of the MHC–p complex to the T cells.209 Thus, adhesion is considered a 
costimulatory signal required to generate TCR signaling and, further, immune response. 
There are several adhesion receptors on T cells that can deliver a costimulatory signal 
including LFA-1. LFA-1 interacts with ICAM-1, -2, and -3.209,210 The expression of 
ICAM-1 on DC is necessary for longstanding interaction between CD8+ T cells and DC for 
activating effector CD8+ T cells and their survival.211 Knocking out ICAM-1 expression 
resulted in elimination of the long-lasting T-cell interaction with DC for memory induction 
and lowering of the production of IFN-γ cytokine.211 This result is attributed to the inability 
to form the IS in the absence of ICAM-1.211 There is a prolonged polarized synapse upon 
DC–T cell interactions before asymmetry T-cell division during mitosis to produce two 
different cells with distinctive functions.212
Efforts made toward understanding the structure, function and mechanisms of interaction 
between LFA-1 and ICAM-1 have produced possibilities of new therapies. Currently, 
several strategies have been developed using LFA-1- and ICAM-1-targeted therapeutics, 
which include antibodies, peptides, peptidomimetics, small molecules, and antisense oligo-
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nucleotides to suppress LFA-1/ICAM-1 costimulatory signal for the treatment of in-
flammation,213 autoimmune diseases,214 allograft rejection,200,215–219 and cancer.220 Other 
than blocking ICAM-1/LFA-1 interaction, the mechanisms of action of these antagonists 
could involve the downregulation of surface expression of these receptors as well as the 
prevention of the formation of active conformation of these molecules.
1. Antibodies—Antibodies have been used to determine the functions of ICAM-1 and 
LFA-1 in disease pathologies, and these antibodies have therapeutic activities in preventing 
organ transplant rejection221–224 and suppressing autoimmune diseases, including 
arthritis,225 insulin-dependent diabetes mellitus,202,203,226 multiples sclerosis,227–231 and 
lupus.232 The first LFA-1/ICAM-1-targeted monoclonal antibody tested clinically was anti-
LFA-1 antibody Odulimomab (antibody 25.3) in bone marrow216,219 and kidney 
transplant,217,218 while anti-ICAM-1 antibody Enlimomab (antibody R6.5 or BIRR1) has 
been investigated in kidney transplant233 and RA.234 Anti-ICAM-1 antibody is progressing 
through phase I and II trials for the treatment of RA.205 Blocking ICAM-1/LFA-1 
interaction using Enlimomab failed to show any benefit in a randomized renal 
transplantation study.235 Efalizumab, a recombinant humanized monoclonal antibody that 
binds to CD11a (the α-subunit of LFA-1), has been successfully used in the treatment of 
psoriasis.207,214,236–242 Recently, a crystal structure of the efalizumab Fab in complex with 
the LFA-1 I-domain reveals that the antibody binds to the I-domain distinct from the 
ICAM-1 binding site and blocks the binding of LFA-1 to ICAM-1 via steric hindrance.243 
Efalizumab, under the trade name Raptiva® has been approved by the FDA in 2003 for the 
treatment of moderate-to-severe plaque psoriasis; it has been withdrawn from the market 
because of increased patient susceptibility to PML.244 Although monoclonal antibodies for 
adhesion molecules have successfully demonstrated effectiveness in suppressing 
autoimmune diseases in patients, the risk of secondary infections and immunogenic response 
has been shown to increase. Therefore, peptides and small molecules are being investigated 
as immunotherapeutics, and these molecules offer distinct advantages in terms of 
development and treatment costs.
2. Peptides—The Siahaan group has discovered several cell adhesion peptides that block 
LFA-1/ICAM-1 interaction (Signal-2). These peptides were derived either from domain-1 of 
ICAM-1 or from α- and β-subunits of LFA-1 (Table II).159,245–252 Studies carried out using 
in vitro cellular models, such as homotypic or heterotypic T cell adhesion or mixed 
lymphocyte reaction, have clearly demonstrated the ability of these peptides to inhibit the 
binding of T cells to APC by blocking the binding of adhesion receptors to their natural 
ligands.245,247–252 It should be noted that although the suppression of autoimmune diseases 
can be accomplished by delivering Signal-2 blockers, inhibiting Signal-2 may also suppress 
the general immune response to fight infections.
3. Antisense oligonucleotides—In addition to expression on immune cells, ICAM-1 is 
also constitutively expressed on endothelial and epithelial cells, and during inflammation 
ICAM-1 expression is upregulated. Antisense oligonuclotide (Alicaforsen, ISIS 2302) binds 
to RNA and blocks the translation of ICAM-1 protein within the cell; this molecule was 
investigated in phase II and III clinical trials for the treatment of Crohn’s disease and 
Manikwar et al. Page 14













ulcerative colitis.253,254 Although the initial trials with a small group of subjects was 
promising, later larger trials in both diseases failed to show efficacies.255–261 The utility of 
ISIS 2302 was also evaluated for treating RA, and this drug was not efficacious in the 
clinical trials.262
B. CD28/B7 Interaction
Interactions between CD28 and B7-1 (or CD80) or B7-2 (or CD86) have a role in T-cell 
differentiation and proliferation. Inhibition of CD28 signal prevents recruitment and 
activation of naïve T cells as well as interfering with epitope spreading. This inhibition is 
being investigated for development of treatments for autoimmune diseases and organ 
transplantations.93,263–269 CD28-deficient mice have impaired immune responses to viral 
antigens or autoantigens,270,271 suggesting that T-cell responses to autoantigens or 
alloantigens are dependent on costimulation through CD28.272 Antibody-induced 
modulation of a costimulatory signal via the CD28 pathway has been shown to prolong 
allograft survival in rats.273\
Administration of anti-CD28 Fab fragments efficiently led to suppression as well as reversal 
in the induction of EAE268 and uveoretinitis274 in mice. The activity of anti-CD28 Fab 
suppresses EAE due to ablation of TNF-α production and prevention of T-cell infiltration 
into the CNS without stimulating CD28.268,269,275,276 Unfortunately, the Fab fragment is 
difficult to develop as a drug because it is rapidly cleared from the body.277 To solve the 
clearance problems, the Fab fragment has conjugated to polyethylene glycol or fused with 
serum albumin, and these conjugates have been shown to have longer half-lives in the 
body.277 Although CD28 blockade using mAb attenuated EAE and prevented subsequent 
relapses, it did not completely eliminate the encephalitogenic response, suggesting that the 
activation of encephalitogenic T cells independent of CD28 costimulation may not have 
been completely abolished. This observation is consistent with findings in CD28-deficient 
mice. CD28−/− mice developed autoimmune heart disease, although it was less severe than 
that observed in heterozygous littermates.270 Similarly, breeding NOD mice with CD28−/− 
was found to exacerbate autoimmunity.278
C. CTLA-4/B7 Interaction
Blocking the CTLA-4/B7 negative signal has been proposed to improve the response of 
cytotoxic T cells to antigen presentation by APC, thus enhancing their activation and 
proliferation.279 The signal transmitted through CTLA-4 leads to dephosphorylation of the 
second messengers in the CD3 complex and subsequently leads to the control of the 
production of various cytokines produced by TH1 and TH2 cells.280,281 It has been suggested 
that CTLA-4 is involved in the development of Treg cells in organ transplantation models,282 
and CTLA-4-deficient animals have been shown to be resistant to immunotolerance.283 A 
single injection of anti-CTLA-4 2 days after immunization in mice resulted in a mild 
increase in severity and incidence of EAE.279 When anti-CTLA-4 mAb was administered on 
the second day after clinical signs of EAE were observed followed by its administration 
every other day for the following 6 days, a marked increase in the disease score was 
observed and there was a considerable increase in the production of IL-2, TNF-α, and IFN-
γ.284 Histological evaluation of mice treated with anti-CTLA-4 mAb showed more 
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inflammation in the brain and the spinal cord compared with those treated with control 
antibody, suggesting that inhibition of CTLA-4 signal enhances the activation and 
proliferation of antigen-reactive T cells.285 Blocking the CTLA-4 signal is not a good 
approach for developing therapeutic agents for autoimmune diseases. In contrast, inhibition 
of CTLA-4 signal can activate T cells for fighting tumors.286 Several clinical trials have 
been conducted using the anti-CTLA-4 antibody to treat melanoma and other types of 
malignancies (Table II). Two of these antibodies, ipilimumab and tremelimumab, have 
reached phase III clinical trials.287
4. BIFUNCTIONAL PEPTIDE INHIBITORS
Recently, we have discovered a novel and selective method to suppress autoimmune 
diseases using bifunctional peptide inhibitor (BPI) molecules that simultaneously target both 
Signal-1 and Signal-2 (Fig. 3). Results from our studies have demonstrated that two different 
BPI molecules (i.e., PLP-BPI and GAD-BPI) can induce immunotolerance in autoimmune 
diseases in two different animal models, EAE288,289 and NOD mice.159 In addition to these 
two BPI molecules, we also have ongoing and promising studies toward developing similar 
molecules to treat collagen-induced arthritis in DBA/1J mice, a mouse model for RA. In the 
case of PLP-BPI, the antigenic-peptide epitope derived from the PLP (PLP139–151) was 
conjugated to LABL peptide derived from αL integrin (CD11a237–246) to make BPI 
molecules.288,289 GAD-BPI is made from GAD208–217 and LABL peptides. We hypothesize 
that the antigenic-peptide fragment (i.e., PLP139–151 and GAD208–217) binds to MHC-II and 
the LFA-1 peptide fragment (LABL) binds to ICAM-1 on the surface of APC. Because both 
peptides are conjugated via a linker, simultaneous binding of BPI to MHC-II and ICAM-1 
will prevent the translocation between TCR:MHC-II-peptide (Signal-1) and ICAM-1/LFA-1 
complexes (Signal-2) that forms the IS. Inhibition of IS formation selectively alters the 
activation of T cells from TH1 to TH2 phenotypes and/or induces the production of Treg 
cells. Because these BPI molecules contain specific antigenic peptides, we hope that we can 
target only a specific subpopulation of T cells involved in the onset and progression of 
autoimmune diseases without affecting the general immune response.
Studies with experimental models of autoimmune disease and allergy have shown that the 
administration of soluble peptides based on known T-cell epitopes leads to suppression of 
the specific response, induction of bystander suppression, and prevention and treatment of 
hypersensitivity. Injections of antigenic peptides, such as PLP139–151266,290 and 
GAD208–217167 in saline, have been shown to suppress the progression of EAE and T1D, 
respectively, in mice models. However, treatment with antigenic peptides is potentially 
dangerous and can lead to fatal anaphylactic reactions. Many researchers have modified 
these antigenic peptides via mutation291 or development of altered peptide ligands (APL)292 
in an effort to improve their therapeutic potential in treating autoimmune diseases as well as 
address their safety concerns.
Our data showed that PLP-BPI has better activity in suppressing EAE than do other 
peptides, including VP2-BPI (a BPI with an epitope peptide derived from Theiler’s 
encephalomyelitis virus capsid protein, VP274–86), which is known to bind to MHC-II in 
SJL/J mice,293 PLP-BPIsLABL (PLP-BPI with a scrambled sequence of LABL), OVA-BPI 
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(BPI in which PLP139–151 has been replaced with OVA326–337 derived from ovalbumin), 
and the unlinked mixture of PLP139–151 and LABL. PLP-BPI-treated mice had very low 
EAE clinical scores and minimal loss in body weight compared with other groups. In 
addition, some of the PLP-BPI-treated mice did not develop the disease.288,289 Similarly, 
dosing regimens designed for therapeutic treatment instead of prophylactic treatment 
showed that BPI was able to reverse disease severity very quickly.289 Some of our 
unpublished work shows that PLP-BPIsPLP (PLP-BPI with a scrambled sequence of 
PLP139–151) has no EAE- suppressing activity, suggesting the significance of a unique 
structure in PLP-BPI such as the need for both PLP139–151 and LABL peptides and covalent 
linking of these two peptides in the same molecule. Also, more importantly, we found out 
that these molecules are highly antigen-specific. We observed that splenocytes isolated from 
PLP139–151-immunized mice responded to in vitro re-stimulation with PLP139–151 but not 
MBP87–89 and vice versa.289 It was also interesting to find that splenocytes isolated from 
Ac-PLP-BPI-NH2 (a modified form of PLP-BPI) showed significantly less proliferation in 
re-call to PLP139–151, suggesting that injection of Ac-PLP-BPI-NH2 reduces and/or 
suppresses the number of PLP139–151- responsive populations. In a parallel study, GAD-BPI 
had the capacity to suppress the progression of T1D in NOD mice as demonstrated by 
significantly less insulitis and lower blood glucose levels in GAD-BPI-treated mice 
compared with control.159
Another important issue we looked at is the safety of these BPI molecules. As with any other 
peptide-based therapy, there is an associated risk involved in the use of BPI such as the 
possibility of an anaphylactic response, a life-threatening immediate hypersensitivity 
reaction caused by injections of the antigen-related peptides. Owing to hypersensitivity 
reactions in patients during phase II clinical trials, development of an MS-targeted peptide 
drug was suspended.294,295 In our studies, i.v. injection of PLP-BPI at 4–5 weeks after 
immunization caused anaphylactic reaction to a much lower number of mice than does 
PLP139–151. Additionally, a modified form of PLP-BPI (i.e., Ac-PLP-BPI-NH2-2 with a 
longer linker and its N- and C-terminal acetylated and amidated, respectively) was found to 
be even less aggressive in inducing anaphylactic reactions.289 We speculate that the lower 
incidence of anaphylaxis in BPI is due to the presence of LABL peptide that inhibits LFA-1/
ICAM-1 interactions at the site of antigen recognition or the addition of another moiety at 
the N- or C-terminal to the parental allergic peptide PLP139–151. Involvement of LFA-1/
ICAM-1- mediated heterotypic aggregation of activated T cells to mast cells has been 
implicated in augmenting mast cell degranulation and histamine release.296
5. PEPTIDE SAFETY
A potential problem that can arise when treating diseases with multiple injections of antigen-
related peptides is the possibility of anaphylactic shock.291,297 As a result of the fact that 
peptides are smaller in size than proteins, it is thought that they are safer and less likely to 
induce an anaphylactic response in the immune system. Despite the numerous advantages of 
peptides over proteins, anaphylactic reactions during treatments involving peptides have 
been widely described in the literature.288,291,297
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In general, the mechanism of anaphylactic response is thought to occur when an antigen 
crosslinks with IgE bound to FcεRI on mast cells, which leads to degranulation and the 
release of histamine and cytokines, both of which are inflammatory mediators.296 The 
administration of anti-IgE antibodies along with myelin-specific peptides during the 
treatment of EAE has been shown to inhibit anaphylaxis, which suggests that IgE plays a 
large role in anaphylaxis when treating with peptides.298
APL have been shown to suppress anaphylaxis in EAE without affecting its activity toward 
myelin-reactive T cells.292 Short linear peptide sequences generally lack the ability to 
crosslink adjacent IgE molecules on mast cells and basophils.299 Because a 
nonimmunogenic peptide sequence can become immunogenic when only one of its amino 
acid residues is altered, care must be exercised in designing an APL so that it retains its 
activity toward its target and does not become more antigenic.
The avoidance of IgE activation is necessary to circumvent allergic response. It is optimal to 
use peptides shorter than 20 amino acids, as longer peptides have been associated with more 
adverse events compared with their shorter counterparts.299 Five-to-six amino acids have 
been shown to be sufficient minimal antigenic determinants.300 Alternatively, APL that can 
bypass the body’s ability to create an anaphylactic response against a peptide without 
affecting its activity toward its target have been shown to work and must be utilized in 
creating effective therapies.
6. MECHANISM OF PEPTIDES THAT TREAT AUTOIMMUNE DISEASES
It has been described before that the immune system functions as a balance between 
pathogenic effector cells and regulatory cells.299 The suppression and activation of these 
two will lead to either an immunogenic response or an immunotolerant response (Fig. 4). 
Autoimmune diseases typically arise due to an imbalance between these two responses. 
Therefore, to combat autoimmune diseases, we must try to restore balance in the immune 
system. One way to restore the balance is by either inducing the suppressive cells or 
activating the regulatory cells.
DC are considered to be the most prominent APC in inducing an autoimmune disease; 
Yamazaki et al.301 and Steinman et al.302 provided excellent reviews on the function of DC 
in tolerance and immune responses. They are believed to send a “danger” signal to induce an 
immunogenic response, but that is not always the case.303 The function of the DC depends 
on whether it is in a mature (activated) or immature state.304
The maturation of DC into a T-cell stimulatory mode is activated by an inflammatory 
stimulus that is initiated by the uptake of an insoluble antigen (Fig. 4, left side).299,304 Once 
the DC is in the mature state, its phenotype changes and there is an upregulation of costi-
mulatory and adhesion molecule expression on its cell surface. Presentation of antigen in 
this way leads to the differentiation of proinflammatory cellular responses.299 Such an 
inflammatory cellular response triggered by a mature DC (mDC) includes the induction of 
TH1 cells that produce IFN-γ and IL-2.304 Other proinflammatory responses include the 
induction of TH17 and the release of IL-17.128 These inflammatory responses triggered 
toward self tissues usually lead to an autoimmune disease such as MS.
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On the other hand, an immature DC (iDC) is one that did not take up and process any 
antigens. It has been shown, using antibodies specific for peptide-free MHC-II molecules, 
that iDC express empty MHC-II molecules on their surface and can bind antigenic peptides 
in solution. These bound antigens can be presented to T cells without internalization and 
processing.305 Soluble peptides that are presented by iDC lead to a differentiation of Treg 
cells (Fig. 4, right side).299 Activation of regulatory T cells leads to the production of 
regulatory cytokines such as IL-10 and TGF-β. Such cytokines have been shown to have an 
important role in ameliorating autoimmune diseases in animal experimental models.306–308 
In the case of some autoimmune diseases, expanding the “regulatory pool” leads to a 
downregulation of the effector response (TH1) and enhancement of the immunosuppressive 
response (TH2). 299
7. PROPOSED BPI MECHANISMS
There are several possible mechanisms that could explain how BPI molecules suppress the 
activation of T cells and result in suppression of autoimmune diseases. The first of these is 
that only the antigenic fragment of BPI molecule binds to MHC-II on the iDC (steady-state 
DC) and is presented to naïve T cells for differentiation to produce Treg cells that generate 
IL-10 (Fig. 5, right side). This proposed mechanism, which is similar to the mechanism of 
action of soluble antigenic peptide as a therapeutic vaccine,299 ignores the role of cell 
adhesion peptide (e.g., cIBR or LABL) on the BPI molecule. It has been shown that 
injection of the BPI molecules generates IL-10;288 however, the kinetics and the amount of 
IL-10 production upon BPI and PLP peptide injections have not been compared. Because 
the BPI molecule has better efficacy than the parent antigenic peptide (PLP),288 it is 
predicted that the amount of IL-10 produced by injecting BPI molecules will be higher than 
that produced by injecting PLP peptide. The second possible mechanism is that the BPI 
molecule binds not only to MHC-II but also to adhesion molecules (e.g., LFA-1 or ICAM-1) 
on iDC. Thus, during the interaction between BPI-loaded iDC and naïve T cells, the BPI 
molecule blocks the IS formation to induce differentiation of naïve T cells to Treg cells. The 
presence of cell adhesion peptide on BPI makes it a more efficient modulator for naïve T 
cell differentiation than the antigenic peptide alone. The third possible mechanism is that the 
BPI molecule simultaneously binds to MHC-II and LFA-1 to block the IS formation during 
the interaction between naïve T cells and mDC (Fig. 5, left side) to suppress the 
differentiation of naïve T cells to TH1 and TH17 cells. There is some indication that the BPI 
molecule induces the generation of IL-4-producing TH2 cells, which may tip the balance to 
lower the production of TH17 and TH1 cells. The increase in IL-4 production was observed 
after BPI injection into the EAE mouse model.288 The mechanism of action of BPI 
molecules may also be a combination of these three proposed mechanisms.
8. CONCLUSIONS
Immunomodulating compounds have been explored as potential treatments for autoimmune 
diseases, such as MS, T1D, and RA among others. However, most of the agents developed 
thus far aim at broad modulation of the immune response and, therefore, may present some 
undesirable side effects. Targeted drug delivery is a more attractive strategy to improve the 
efficacy and reduce the side effects of these immunomodulating drugs. In our studies, we 
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hope to design BPIs that target only a subpopulation of T cells responsible for the 
progression of the disease without affecting the general immune response. Although it has 
not been clearly elucidated, BPI-based therapies work either by inhibiting the formation of 
the IS by blocking both Signal-1 and Signal-2 or by shifting the T-cell subpopulation into 
Tregs and/or TH2-like phenotype. The detailed mechanisms of action of BPI-type molecules, 
including the antigen-specific immunosuppressive activity as well as its safety, are being 
investigated in depth in our current studies. Additionally, we are looking at ways of 
improving the structure and sequence of BPI to provide a more efficient and well-tolerated 
immunotherapy.
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Mechanism of immunological synapse formation during T cell and APC interaction. (A) 
Initial contact between Signal-1 (TCR/MHC-II-peptide complex) and Signal-2 (LFA-1/
ICAM-1complex). (B) Translocation of Signal-1and Signal-2 to form c-SMAC and p-
SMAC of the immunological synapse. APC, antigen-presenting cell; SMAC, 
supramolecular activation clusters; ICAM-1, intercellular adhesion molecule-1; MHC, major 
histocompatibility complex; TCR, T-cell receptors; LFA, leukocyte function-associated 
antigen; p-SMAC, peripheral SMAC.
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Signaling molecules involved in the interface of T cell and APC interaction. The interaction 
between T cell and APC involves several pairs of receptors (Signal-1 and -2) and is 
associated with the release of cytokines (Signal-3). APC, antigen-presenting cell.
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The proposed binding of the BPI molecule to MHC-II and ICAM-1, which inhibits the 
translocation of Signal-1 and Signal-2. ICAM-1, intercellular adhesion molecule-1; MHC, 
major histocompatibility complex; BPI, bifunctional peptide inhibitor.
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The proposed mechanism of activation and suppression of immune response during 
autoimmune diseases. On the left, interaction between mature/activated DC and naïve T 
cells is mediated by MHC-II antigen/TCR complex (Signal-1) in the presence of the 
costimulatory signal (Signal-2) that leads to differentiation intoTH1 and TH17 cells. On the 
right, interaction between immature/steady-state DC and naïve T cells is mediated by MHC-
II antigen/TCR complex (Signal-1) in the absence of the costi-mulatory signal (Signal-2) 
that leads to differentiation intoTreg cells. Treg cells produce IL-10 that suppresses the 
proliferation of TH1 and TH17. MHC, major histocompatibility complex; TCR, T-cell 
receptors; DC, dendritic cells.
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Potential mechanism of BPI molecules in altering the differentiation of naïve T cells upon 
interaction with immature and mature DC. On the right, interaction of steady-state/immature 
DC with BPI molecule produces differentiation of naïve T cells to IL-10-producingTreg 
cells. IL-10 induces the proliferation of immunosuppressant TH2 cells. On the left, 
interaction of BPI molecule with mature/activated DC induces immunosuppressant TH2 cell 
differentiation. MHC, major histocompatibility complex; TCR, T-cell receptors; DC, 
dendritic cells; BPI, bifunctional peptide inhibitor.
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Table I
List of Candidate Autoantigens in MS, T1D, and RA
Disease Antigen References
Multiple sclerosis Proteolipid protein (PLP)
Myelin basic protein (MBP)
Myelin oligodendrocyte glycoprotein (MOG)
Astrocyte-protein S100β
309
Type 1 diabetes Glutamic acid decarboxylase (GAD)




Rheumatoid arthritis Human cartilage gp-39
Cartilage proteins melanoma inhibitory activity (MIA)
Type II collagen
Citrullinated proteins (e.g., fibrin)
310–316
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Table II
Antibodies and Peptides That Have Been Investigated for Blocking Signal-2 in Autoimmune Diseases, Organ 
Transplantation, and Cancer
Signal-2 Receptor Peptide/protein ligand Target disease References
LFA-1/ICAM-1 Anti-LFA-1 mAb (Odulimomab, Efalizumab) Psoriasis, Type 1 diabetes, and transplantation 203,214,216–219,237
LFA-1/ICAM-1 Anti-ICAM-1 mAb (Enlimomab) Rheumatoid arthritis, Type 1 diabetes, and 
transplantation
226,233,234
LFA-1/ICAM-1 Cyclo(1,12)-PenPRGGSVLVTGC (cIBR) Rheumatoid arthritis, inflammation, and 
immunosuppression
246,250
LFA-1/ICAM-1 Cyclo(1,12)-PenITDGEATDSGC (cLABL) Rheumatoid arthritis, inflammation, and 
immunosuppression
250,251,317,318
LFA-1/ICAM-1 Cyclo(1,9)-CLLRMRSIC Inflammation 319
B7/CD28 Anti-CD28 mAb Transplantation 320
B7/CTLA-4 Anti-CTLA4 mAb (Ipilimumab and Tremelimumab) Melanoma and other types of malignancies 287
B7/CTLA-4 Abatacept (CTLA4-Ig) Rheumatoid arthritis 321
CTLA, cytotoxic T-lymphocyte antigen; mAb, monoclonal antibody; ICAM, intercellular adhesionmolecule.
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